ASAna Soriano-Martín

Ana Soriano-Martín

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ana Soriano-Martín has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of Quantitative Differences of Classic Methods, Fungal Biomarkers, and T2Candida for Assessing the Central Venous Catheter Origin of Candidemia

    by Ana Soriano-Martín, Antonio Vena, María Jesús Pérez-Granda, Alessandro Limongelli, Almudena Burillo, Pilar Escribano, Jesús Guinea, Malgorzata Mikulska, Daniele Roberto Giacobbe, Marina Machado, et al.

    Background: This study was conducted to investigate the diagnostic value of fungal biomarker differentials and T2Candida polymerase chain reaction (PCR) from catheter and peripheral blood samples and to re-evaluate classical conservative methods, such as differential time to positivity of blood cultures (BCs), for the early identification of catheter-related candidemia (CRC) before catheter removal. Methods: This prospective study was conducted (March 2023–April 2025) in 2 tertiary hospitals in Spain and Italy. Adults (aged ≥18 years) with candidemia and a central venous catheter in place at diagnosis were included, provided catheter removal occurred within 48 hours of index BC positivity. CRC was defined in patients with candidemia who showed 1 or 2 of the following criteria in the catheter tip: (1) ≥ 15 CFU/plate (Maki technique) or ≥ 1000 CFU/mL (sonication) and (2) any Candida growth on the catheter tip. Blood samples were collected from peripheral veins and catheter lumens to compare the differentials of 1,3-β-D-glucan (BDG), Candida albicans germ tube antibodies, mannan antigen, antimannan antibody, and T2Candida PCR results. Diagnostic metrics were calculated for each test. Results: Of 179 episodes of candidemia reviewed, 28 (15.6%) met the inclusion criteria (13 in Spain, 15 in Italy). CRC was confirmed in 11 patients (39.3%) using criterion 1 and in 15 patients (53.6%) using criterion 2. BDG differentials (any difference) demonstrated the highest diagnostic accuracy as follows: sensitivity 81.82%, specificity 82.35%, positive predictive value 75.00%, negative predictive value 87.50%, and overall accuracy 82.14% (criterion 1). However, stricter BDG thresholds (≥20 or ≥30 pg/mL) and the application of criterion 2 reduced the sensitivity. Other biomarkers and T2Candida PCR demonstrated low sensitivity (0%–40%) and variable specificity (25%–100%), with overall accuracies of <64%. Differential time to positivity of BCs yielded a sensitivity of 72.73% and a specificity of 52.94%, with limited accuracy. Conclusions: None of the investigated methods achieved sufficient accuracy to diagnose CRC without catheter removal. Despite the limited sample size, this study emphasizes the limitations of current diagnostic approaches and the need for novel tools for reliable noninvasive identification of CRC.

  • Open Access

    Comparative effectiveness of echinocandins and liposomal amphotericin B for fluconazole-resistant Candida parapsilosis bloodstream infections

    by Antonio Vena, Claudia Bartalucci, Marco Muccio, Giusy Tiseo, Patricia Muñoz, Mario Cesaretti, Vincenzo Di Pilato, Anna Marchese, Ramona Barbieri, Arianna Forniti, et al.

    Current therapeutic options for fluconazole-resistant Candida parapsilosis (FLZR-CP) bloodstream infections (BSI) are limited to echinocandins and liposomal amphotericin B (L-AmB). To the best of our knowledge, no real-world comparative effectiveness studies have assessed these agents. This study aimed to compare the effectiveness of echinocandins and L-AmB for the treatment of FLZR-CP BSI. This retrospective, observational study was conducted in two hospitals in Italy between January 2018 and December 2022. Eligible patients were adults (≥18 years old) with microbiologically confirmed FLZR-CP BSI who received targeted therapy with either echinocandins or L-AmB. Patients were matched (2:1) based on age, Charlson comorbidity index, presence of sepsis or septic shock, time to appropriate antifungal therapy (≤48 hours or > 48 hours from diagnosis), and infection source. A total of 63 patients were included (42 in the echinocandin group and 21 in the L-AmB group). In Cox regression, targeted therapy with echinocandins was not associated with increased mortality (adjusted hazard ratio 1.40; 95% confidence interval [CI] 0.33–5.92, P = 0.645). An exploratory sensitivity analysis including patients who did not receive source control yielded consistent results ( P = 0.491). Furthermore, in the multivariable regression analysis, echinocandin therapy was not associated with an increased risk of persistent fungemia (adjusted odds ratio 1.61: 95% CI 0.43–5.99, P = 0.476). Treatment with echinocandins and L-AmB resulted in similar 30-day mortality and persistent fungemia rates in patients with FLZR-CP BSI. These findings confirm that echinocandins are a viable treatment option for C. parapsilosis BSI, even for patients with fluconazole-resistant strains.


  • Open Access

    Rezafungin Utilisation in Real Life—FungiScope Results From Europe and the United States

    by Ilana Reinhold, Giovanni Mori, Massimiliano Lanzafame, Alessandro Limongelli, Antonio Vena, Julia Götz, Stilla Bauernfeind, Frank Hanses, Lukas Tometten, Michael Mayer, et al.

    Background: Rezafungin, a novel echinocandin with once‐weekly intravenous dosing, offers potential advantages for outpatient parenteral antifungal therapy (OPAT) in invasive candidiasis (IC). While clinical trial data support its efficacy and safety, real‐world experience remains limited.Methods: A retrospective analysis of patients treated with rezafungin across Germany, Italy, Spain, and the United States between January 2024 and June 2025 was conducted. Data was collected via the FungiScope registry. Clinical characteristics, indications for rezafungin, outcomes, safety, and logistical aspects of administration were evaluated.Results: Fifteen patients were included, fourteen with IC; one with chronic pulmonary aspergillosis. Regarding patients with IC, the median age was 65.5 years; 43% were female. The most frequently identified pathogens were Candida glabrata (57%) and Candida parapsilosis (21%). Primary indications for rezafungin were intravascular (36%) and osteoarticular infections (36%). Rezafungin was mainly selected to enable OPAT (86%) or due to fluconazole resistance (36%) or drug–drug interactions (14%). The median treatment duration was 9 weeks (range: 1–38 weeks). One mild adverse event occurred (cutaneous photosensitivity), but rezafungin was otherwise well tolerated. Complete clinical or mycological response was observed in 36% at day 30, and partial response in 50% of patients. Access differed substantially across centres due to administrative and reimbursement hurdles, affecting treatment transition to rezafungin in 71% of patients with IC.Conclusions: Rezafungin was effective and well tolerated in this cohort, particularly in patients requiring long‐term treatment. Administrative and logistical hurdles remain significant barriers to its widespread use. Facilitated access and enhanced awareness may improve patient outcomes by supporting early initiation and continuity of care.


  • Open Access

    Trends in Candidemia Over the Last 14 Years: A Comparative Analysis of Candida parapsilosis and Candida albicans

    by Ana Soriano-Martín, Pilar Escribano, Marina Machado, Jesús Guinea, Elena Reigadas, Paloma García-Clemente, Emilio Bouza, Patricia Muñoz

    Background: Data on the trends of the incidence of candidemia caused by C. albicans and C. parapsilosis in recent years are very limited. At the same time, factors that predispose to candidemia, caused by both species and the epidemiology of hospital transmission, are not well known. Our study analyzed 14 years of candidemia in a single institution in order to compare the incidence, clinical outcomes, and transmission patterns of both species. Methods: We conducted a retrospective study (2010–2023) in a 1236-bed tertiary hospital. We included all episodes of candidemia due to C. albicans and C. parapsilosis and collected the epidemiological, clinical, and microbiological characteristics of the patients. Incidence trends were calculated per hospital admission and population. Antifungal susceptibility testing followed European Committee on Antimicrobial Susceptibility Testing guidelines, and genotyping used species-specific microsatellites. Results: Among 576 episodes of candidemia, 269 (46.7%) were caused by C. albicans and 110 (19.1%) by C. parapsilosis. The incidence of candidemia per 1000 admissions/y and 100 000 population/y remained stable for both species. C. parapsilosis affected younger patients with fewer comorbidities and lower mortality than C. albicans. The catheter was the main source in both groups, but genotyping revealed no C. parapsilosis clusters, suggesting the absence of a significant horizontal transmission. We did not have a single episode of fluconazole-resistant C. parapsilosis candidemia. Conclusions: Our data do not suggest an increasing trend in the incidence of C. albicans and C. parapsilosis candidemia in recent years. Candidemia caused by both species is not significantly transmitted from patient to patient in the hospital. The genotypical distribution of fluconazole-resistant C. parapsilosis should be further studied.


  • Open Access

    Candida spp.: the burden of a microorganism in a microbiology department

    by Ana Soriano-Martín, Roberto Alonso, Marina Machado, Elena Reigadas, Patricia Muñoz, Emilio Bouza

    There is no precise information available on the entire workload of isolating a specific microorganism in a clinical microbiology laboratory, and the costs associated with it have not been specifically estimated. In this descriptive retrospective study conducted at the microbiology department of a general teaching hospital from January 2021 to December 2022, we assessed the workload associated with identifying Candida species in all types of clinical samples and patients. Costs were estimated from data obtained from the hospital’s finance department and microbiology laboratory cost records. In 2 years, 1,008,231 samples were processed at our microbiology department, of which 8,775 had one or more Candida spp. isolates (9,683 total isolates). Overall, 5,151 samples with Candida spp. were identified from 2,383 inpatients. We isolated Candida spp. from 515.3 samples/100,000 population/year and from 92 samples/1,000 hospital admissions/year. By sample type, 90.8% were superficial, mainly mucosal. Only 9.1% Candida spp. were isolated from deep, usually sterile, samples, being mostly from ordinarily sterile fluids. Candida albicans was the main species (58.5%) identified, followed by C. parapsilosis complex, C. glabrata , C. tropicalis, and C. krusei . In admitted patients, the incidences of samples with Candida spp. isolates were 302.7 samples/100,000 population/year and 54 samples/1,000 admissions/year. The average cost of isolating and identifying Candida spp. was estimated at 25€ per culture-positive sample. To our knowledge, this is the first attempt to gage the workload and costs of Candida spp. isolation at a hospital microbiology department. These data can help assess the burden and significance of Candida isolation at other institutions and also help design measures for streamlining. IMPORTANCE: We believe that this work is of interest because at present, there is no really accurate information available on the total workload involved in isolating a specific microorganism in a clinical microbiology laboratory. The costs related to this have also not been described. We have described the unrestricted workload of Candida spp. in all types of samples for all types of species and patients. We believe that this information would be necessary to collect and share this information as well as to collect it in a standardized way to know the current situation of Candida spp. workload in all clinical microbiology laboratories.


  • Open Access

    Unresolved issues in the diagnosis of catheter related candidemia: A position paper

    by Ana Soriano-Martín, Patricia Muñoz, Julio García-Rodríguez, Rafael Cantón, Antonio Vena, Matteo Bassetti, Emilio Bouza

    The incidence and recent trends of candidemia and the contribution of the COVID-19 pandemic to its evolution are not well documented. The catheter is a major focus of Candida spp. infections, but the methods used to confirm the origin of candidemia are still based on the data generated for bacterial infection. The presence of Candida spp. on the tip of a removed catheter is the gold standard for confirmation but it is not always possible to remove it. Conservative methods, without catheter removal, have not been specifically studied for microorganisms whose times of growth are different from those of bacteria and therefore these results are not applicable to candidemia. The different Candida species do not have a particular tropism for catheter colonization and fungal biomarkers have not yet been able to contribute to the determination of the origin of candidemia. Techniques such Candida T2 Magnetic Resonance (T2MR) has not yet been applied for this purpose. Finally, there is not yet a consensus of how to proceed when Candida spp. is isolated from an extracted catheter and blood cultures obtained from simultaneous peripheral veins are negative. In this lack of firm data, a group of experts has formulated a series of questions trying to answer them based on the literature, indicating the current deficiencies and offering their own opinion. All authors agree with the conclusions of the manuscript and offer it as a position and discussion paper.